First oral JAK inhibitor given FDA approval for treating adolescents with alopecia areata.

Published Date: 30 Jun 2023

Ritlecitinib (Litfulo), a Janus kinase (JAK) inhibitor, has been approved by the US FDA (Food and Drug Administration) for use in adults and adolescents with.

Read Full News

Latest News

HPV Vaccination Underutilized in Transplant Recipients

HPV vaccination rates were low among solid organ transplant recipients, a study shows.

Navigating GLP-1 Hair Loss With Your Patients

Patients are increasingly anxious about hair shedding on GLP-1s. Here is what the latest research shows, why it happens, and how to manage it in the clinic.

Self-Detection, Male Sex Linked to Thicker Melanomas

Detection patterns, reasons for consultation, and sex-based differences strongly influence tumour thickness and prognosis in young adults with cutaneous melanoma, a retrospective study finds.

France Reports New Local Arboviral Infections in 2026

Imported arboviral infections are climbing in France, with locally acquired cases now reported. Clinicians are urged to spot early clues and report suspected cases fast.

What to Tell Patients Worried About PFAS Exposure

PFAS exposure is widespread, but clinicians can help patients understand the main sources, potential health effects, and practical ways to reduce risk.

Cherry Angiomas Linked to Neurofibromatosis Type 1

People with neurofibromatosis type 1 often have cherry angiomas, an unrecognized vascular manifestation of NF1, a study indicates.

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Todays Updates

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Latest News

HPV vaccination rates were low among solid organ transplant recipients, a study shows.

Patients are increasingly anxious about hair shedding on GLP-1s. Here is what the latest research shows, why it happens, and how to manage it in the clinic.

Detection patterns, reasons for consultation, and sex-based differences strongly influence tumour thickness and prognosis in young adults with cutaneous melanoma, a retrospective study finds.

Imported arboviral infections are climbing in France, with locally acquired cases now reported. Clinicians are urged to spot early clues and report suspected cases fast.

PFAS exposure is widespread, but clinicians can help patients understand the main sources, potential health effects, and practical ways to reduce risk.

People with neurofibromatosis type 1 often have cherry angiomas, an unrecognized vascular manifestation of NF1, a study indicates.

News All Time

Can Apremilast Curb PsA in Patients With Psoriasis?

A 24-week course of the phosphodiesterase 4 inhibitor apremilast may ease skin symptoms and joint tenderness while keeping early bone changes stable in high-risk patients with psoriasis.

WHO Defends Immunisation Schedules After Trump Orders Fewer Childhood Shots

The World Health Organization on Tuesday defended the science-based process used to determine childhood immunisation schedules after U.S. President Donald Trump signed an...

Pancreatic Cancer Specialists Getting a Jump on Daraxonrasib

In the wake of striking survival data, more than 2000 US patients are receiving daraxonrasib before FDA approval.

Trump Order Reduces US Vaccine Schedule, Seeks to Split MMR Shot

U.S. President Donald Trump signed an executive order on Monday calling for fewer childhood vaccinations by limiting the inoculation schedule to 11 immunizations, which he...

Alopecia in Transgender Patients: Management Strategies

Low-dose oral minoxidil ranks high as a first-line alopecia treatment option for transmasculine individuals and, especially in combination with spironolactone, for transfeminine patients.

Wellness Peptides Are Trending: Are They Safe?

Growing interest in unapproved peptides is raising concerns about weak human evidence, uncertain product quality, self-administration, and poorly understood long-term safety.

Skin Cancer Prevention Gaps Seen in Indigenous Adults

A survey of American Indian/Alaska Native adults in South Dakota finds low sunscreen use and gaps in skin cancer risk perception and knowledge.

Hemangiomas: Absence of One Feature May Rule Out Syndrome

A systematic review of patients with LUMBAR syndrome found that the anatomic midline was involved in all cases, raising the possibility that this is a diagnostic criterion.

Hyperinsulinemic Hypoglycemia: Looking Beyond Insulinoma?

A distinctive metabolic signature may identify rare insulin receptor disorders earlier, helping clinicians avoid unnecessary insulinoma investigations.

FDA Approves Replimune Skin Cancer Drug After Rejections

The accelerated approval follows FDA concerns about the single-arm evidence supporting the treatment.

TikTok Turns Isotretinoin Into a Beauty Trend

Social media has fueled new demand for isotretinoin, but the drug’s true value and its best-known risks remain defined by evidence, not influencer hype.

Manufacturer Files for Botox Approval for Jawline Contouring

After positive findings from phase 3 trials, Allergan Aesthetics submits sBLA to the FDA for onabotulinumtoxinA, to improve the appearance of the masseter muscle.

Combo Therapy May Clear Stubborn Warts Faster

Combining topical urea with carboxytherapy may help reduce lesion size more effectively and achieve faster clearance than urea alone in patients with treatment-resistant common warts.

Deucravacitinib Shows Sustained Efficacy and Safety in PsA

Deucravacitinib shows greater efficacy than placebo in adults with active psoriatic arthritis at week 16, with sustained benefits through week 52 and a well-tolerated safety profile.

CSCC Incidence, NMSC Mortality Rise in England

The incidence of keratinocyte cancer rose in England from 2013 to 2022, with a stabilising incidence of BCC, an increasing incidence of cutaneous squamous cell carcinoma, and rising NMSC mortality.

Surgeons Warn of 'Regulatory Gap' in Cosmetic Surgery

Surgical royal colleges warn the government's delayed consultation leaves patients exposed to under-qualified practitioners.

Recommended News For You

One possible target in acute myeloid leukemia is the reductive carboxylation of glutamine.

Oleanolic acid from grapes may increase chemotherapy effectiveness

Patients value communication skills from cancer surgeons across six key areas, according to research

Year in Review: Multiple Myeloma

Significant worldwide disparities seen in availability and timeliness of new cancer drugs

In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.

New Zealand and Australian breast cancer rates among the highest in the world, global study finds

Recommended Articles For You

Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice 

Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer 

Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights 

Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

1.

Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care

2.

Progressive Insights in Hematology in the Digital Era

3.

Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective

4.

Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources

5.

The Rise of Immunotherapy: New Advances in Cancer Treatment

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care

2.

Blood Clotting Disorders Explained

3.

Sickle Cell Disease Explained

4.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

5.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot